[ad_1] TAIPEI, 24 octobre 2025 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE : 7754) annonce aujourd’hui que l’Agence des produits alimentaires et médicamenteux (FDA) des États-Unis a accordé la désignation Fast Track à AJ201, un […]
Tag: AnnJi Pharmaceutical Co.
FDA erteilt Fast-Track-Status für AJ201, eine bahnbrechende Therapie für die Kennedy-Krankheit
[ad_1] TAIPEI, 23. Oktober 2025 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food & Drug Administration) AJ201, dem ersten Medikament seiner Klasse zur Behandlung der […]
FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy’s Disease
[ad_1] TAIPEI, Oct. 23, 2025 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy […]
FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy’s Disease
[ad_1] TAIPEI, Oct. 22, 2025 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy […]
